

41

1645

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/070,647	RECEIVED
	Filing Date	06/18/2002	
	First Named Inventor	M. Bernfield	OCT 31 2003
	Art Unit	1645	
	Examiner Name	J.E. Graser	TECH CENTER 1600/2900
Attorney Docket Number	701039-048929		
Total Number of Pages in This Submission			

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Certificate of Mailing; Return Receipt Postcard.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	The Commissioner is authorized to charge the NIXON PEABODY LLP Deposit Account No. 50-0850 for any fee deficiencies associated with this submission.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David S. Resnick (Reg. No. 34,235) NIXON PEABODY LLP, 101 Federal Street, Boston, MA 02110
Signature	
Date	10/27/03

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:			
Typed or printed name	Nicole M. Gignac		
Signature		Date	10/27/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Docket No. 701039-048929

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
RECEIVED

OCT 31 2003

Applicant: Children's Medical Center Corporation
Inventors: BERNFIELD, M. and PARK, P.
U.S. Serial No.: 10/070,647
Filed: 18 June 2002
For: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

Group Art Unit: 1645

Examiner: Jennifer E. Graser

TECH CENTER 1600/2900

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);
2. Response to Restriction Requirement (1 pg.);
3. Return Receipt Postcard;

is on the date shown below being:


MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202


Date: October 27, 2003

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.


Signature

Nicole M. Gignac
(type or print name of person certifying)



Docket No. 701039-048929

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
RECEIVED

OCT 31 2003

Applicant: Children's Medical Center Corporation
Inventors: BERNFIELD, M. and PARK, P.
U.S. Serial No.: 10/070,647
Filed: 18 June 2002
For: METHOD FOR TREATING AND PREVENTING BACTERIAL INFECTION

Group Art Unit: 1645

Examiner: Jennifer E. Graser

TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date

10/27/2003

Nicole M. Gignac

(type or print name of person mailing paper)


Signature of person mailing paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of October 2, 2003 in the above-identified application, Applicants elect Group I, Claims 1 – 10, without traverse, drawn to a method for treating a bacterial infection comprising determining whether the bacterium causing the infection is capable of enhancing host cell syndecan-1 shedding and administering an effective amount of a compound that inhibits syndecan-1 shedding, however when the bacterium is *P.aeruginosa* the compound cannot be genistein or tyrphostin A47.


FEE AUTHORIZATION

Should any fee deficiencies be associated with this submission, the Commissioner is authorized to such deficiencies to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Date: 10/27, 2003

Customer No.: 26248

Respectfully submitted,


David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
Tel: (617) 345-6057/1370
Fax: (617) 345-1300